Enara Bio
Updated: February 23, 2026
CEO Kevin Pojasek
Country: UK | Funding: $50M (+)
Founded: 2016
Website: https://enarabio.com/
Enara Bio develops targeted cancer immunotherapies using its Dark Antigen discovery engine and optimized T-cell activator platform. Dark Antigens cluster - is a rich source of novel cancer targets derived from genomic regions previously considered "dark" or non-coding. The EDAPT platform helps to identify these dark targets. The company has also developed EnTiCE platform for creating bispecific T-cell activators against these identified targets to improve treatment outcomes for a wide range of cancer patients. Enara Bio's pipeline includes clinical trials against solid tumors, non-small cell lung cancer, melanoma, and ovarian cancer. The startup is backed by leading biotech investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, and SV Health Investors.
Founded: 2016
Website: https://enarabio.com/
Enara Bio develops targeted cancer immunotherapies using its Dark Antigen discovery engine and optimized T-cell activator platform. Dark Antigens cluster - is a rich source of novel cancer targets derived from genomic regions previously considered "dark" or non-coding. The EDAPT platform helps to identify these dark targets. The company has also developed EnTiCE platform for creating bispecific T-cell activators against these identified targets to improve treatment outcomes for a wide range of cancer patients. Enara Bio's pipeline includes clinical trials against solid tumors, non-small cell lung cancer, melanoma, and ovarian cancer. The startup is backed by leading biotech investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, and SV Health Investors.
